Lobe

Pentec Health and Lobe Sciences Announce Exclusive Distribution Agreement, Initial Availability of Altemia, First U.S. Medical Food for People With Sickle Cell Disease

Retrieved on: 
Thursday, September 21, 2023
Molecule, Insurance, CSE, GLEN, DHA, SCD, Health, Health equity, Inherited disorders of trafficking, Research, Biomarker, History, Life expectancy, Pain, Pharmacist, Patient, Physician, Swelling, Nursing, Sickle cell disease, Mouse, Blood cell, Rare, Disease, Pharmaceutical industry, Dietary supplement, VOC, Lobe, Medicine

GLEN MILLS, Pa., Sept. 21, 2023 /PRNewswire-PRWeb/ -- Pentec Health, Inc. (Pentec) and Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") are pleased to announce an exclusive U.S. distribution agreement and the initial availability of Altemia™ – the first medical food in the U.S. designed specifically for children and adults with sickle cell disease (SCD).

Key Points: 
  • – Pentec Health, Inc. (Pentec) and Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") are pleased to announce an exclusive U.S. distribution agreement and the initial availability of Altemia™ – the first medical food in the U.S. designed specifically for children and adults with sickle cell disease (SCD).
  • (Pentec) and Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") are pleased to announce an exclusive U.S. distribution agreement and the initial availability of Altemia™ – the first medical food in the U.S. designed specifically for children and adults with sickle cell disease (SCD).
  • The initial availability of Altemia in select markets aligns with National Sickle Cell Awareness Month, which focuses on the need for research and treatment of SCD.
  • Dietary supplementation with docosahexanoic acid (DHA) increases red blood cell membrane flexibility in mice with sickle cell disease.

Lobe Sciences, Ltd. Announces Amendment to the Acquisition of Altemia™ & Company

Retrieved on: 
Thursday, September 14, 2023
Research, Genetics, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Transfer, Intellectual property, Amendment, CSE, Sample, Sickle cell disease, Milestone, Sale, Patient, Rare disease, Rare, Fine chemical, Sales, Lobe

Pursuant to the Amendment, the 76,000,000 common shares of the Company (each a “Lobe Share”) previously issued to the Altemia members (“Selling Members”) shall be returned by the Selling Members to the Company and cancelled by the Company pursuant a share cancellation agreement.

Key Points: 
  • Pursuant to the Amendment, the 76,000,000 common shares of the Company (each a “Lobe Share”) previously issued to the Altemia members (“Selling Members”) shall be returned by the Selling Members to the Company and cancelled by the Company pursuant a share cancellation agreement.
  • collectively, clauses (a) through (d) are referred to as a “Milestone”.
  • Each Milestone a, b, c and d represents 19,000,000 Lobe Shares, and
    Within ten (10) days of Selling Member providing Lobe a written notice to release some or all of the then available shares with respect to which the applicable Milestone has been met.
  • Each Altemia member may in such notice designate one or more third parties to receive some or all of any such Lobe Shares then available for release.

Lobe Sciences Appoints Baxter Phillips III, MBA as Chief Operating Officer

Retrieved on: 
Wednesday, June 7, 2023
Health, Fitness & Nutrition, Other Science, Research, Science, Pharmaceutical, Biotechnology, SCC, CSE, College, Friends, Marketing, Clinical trial, Quality of life, MBA, History, Pain, College of William & Mary, Phillips, CGMP, Patient, Anti-transglutaminase antibodies, Sickle cell disease, Rare, Hampden–Sydney College, INSM, Management, Pharmaceutical industry, Insming, Lobe, Biology

Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced the appointment of Baxter Phillips III, MBA, to the newly created position of Chief Operating Officer (COO) effective immediately.

Key Points: 
  • Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced the appointment of Baxter Phillips III, MBA, to the newly created position of Chief Operating Officer (COO) effective immediately.
  • Mr. Phillips will also serve as President, Altemia and Company, LLC, a Lobe Sciences wholly owned subsidiary focused on treatments and support for patients with sickle cell anemia.
  • Phillips will report directly to Chairman and Chief Executive Officer Philip J.
  • In October of 2022, Mr. Phillips was appointed to Lobe Sciences' Board of Directors, where he will also continue to serve the Company.

Lobe Sciences Announces Commercial Distribution Agreement With Pentec Health for US Launch of Altemia™

Retrieved on: 
Wednesday, May 17, 2023
Biotechnology, Technology, Managed Care, Health, Pharmaceutical, Neurology, Research, Fitness & Nutrition, Science, Clinical Trials, Food Tech, Partnership, CSE, DHA, SCD, Biomarker, Lobe, CGMP, Patient, Sickle cell disease, United, Caregiver, Medical food, Pharmaceutical industry, Nursing

Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat orphan diseases today announced it has entered into a commercial distribution agreement for the supply and distribution of Altemia™ with Pentec Health, Inc. (“Pentec Health”), a nationwide provider of clinical nutrition and specialty care services addressing complex needs for patients.

Key Points: 
  • Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat orphan diseases today announced it has entered into a commercial distribution agreement for the supply and distribution of Altemia™ with Pentec Health, Inc. (“Pentec Health”), a nationwide provider of clinical nutrition and specialty care services addressing complex needs for patients.
  • Under the terms of the distribution agreement, Pentec Health will receive the exclusive rights to distribute Altemia™ in the United States and US territories.
  • Through Pentec Health, Altemia™ will be available to pediatric and adult patients with SCD throughout the United States.
  • Pentec Health is extremely well-positioned and experienced in the medical food marketplace and they will ensure it reaches key healthcare providers and patients.

Lobe Sciences Announces Data Demonstrating That Its Combination Therapeutic Candidates are Significantly More Effective Than Monotherapy in mTBI and PTSD

Retrieved on: 
Tuesday, September 28, 2021
News, University of Miami, Trauma, Lobe, Memory, Otorhinolaryngology, Therapy, CGMP, OTC Markets Group, University, CSE, Multimedia, NAC, Physician, Population, Concussion, IP, CEO, THE, Company, Growth, TBI, Mental health, COVID-19, Post-traumatic stress disorder, View, Research, Acetylcysteine, Brain, PTSD, Learning, Forward-looking statement, THIS, Time, Psilocybin, Pharmaceutical industry, Risk management

The rodents treated with the combination of psilocybin and NAC performed statistically significantly better (P

Key Points: 
  • The rodents treated with the combination of psilocybin and NAC performed statistically significantly better (P
  • Philip Young, CEO of Lobe stated, "I am thankful to Dr. Hoffer and his team for their excellent work.
  • Lobe Sciences is a life sciences company focused on psychedelic medicines.
  • This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts.

Lobe Sciences to Present at the Benzinga Global Small Cap Conference

Retrieved on: 
Thursday, May 6, 2021
XC2, Small cap, Lobe

b'Vancouver, British Columbia--(Newsfile Corp. - May 6, 2021) - Lobe Sciences Ltd.\xc2\xa0(CSE: LOBE) (OTC Pink: GTSIF)\xc2\xa0("Lobe" or the "Company") is pleased to announce that it will be presenting at the Benzinga Global Small Cap Conference taking place on May 13-14, 2021.

Key Points: 
  • b'Vancouver, British Columbia--(Newsfile Corp. - May 6, 2021) - Lobe Sciences Ltd.\xc2\xa0(CSE: LOBE) (OTC Pink: GTSIF)\xc2\xa0("Lobe" or the "Company") is pleased to announce that it will be presenting at the Benzinga Global Small Cap Conference taking place on May 13-14, 2021.
  • "\nFor more information and/or to register for a free spectator pass for the conference please visit: https://www.benzinga.com/events/small-cap/global/\nThe Benzinga Global Small Cap Conference bridges the gap between Small Cap companies, investors, and traders.
  • Learn about small cap investing with clearly defined educational modules, take a look at a curated group of small cap investment opportunities, and connect with the global small cap audience in an intimate, virtual setting.\nLobe is a life sciences company focused on psychedelic medicines.
  • Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect.

Lobe Sciences Appoints Ilan Hayman to Advisory Board

Retrieved on: 
Tuesday, April 6, 2021
Lobe, Hayman

Vancouver, British Columbia--(Newsfile Corp. - April 6, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce the appointment of Mr. Ilan Hayman, B.IS, ITIL Cert, M. ProjMngt to its Advisory Board.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - April 6, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce the appointment of Mr. Ilan Hayman, B.IS, ITIL Cert, M. ProjMngt to its Advisory Board.
  • Philip Young, CEO and Director of Lobe states, "We are very pleased to welcome Ilan to our Advisory Board.
  • Ilan's association with Mind Medicine Australia will allow Lobe to be introduced to this organization's mandate and we are excited about fostering this relationship.
  • Ilan Hayman states, "It is a pleasure to join Lobe during this exciting time for the company.

Lobe Sciences Becomes Enterprise Member of NFL Alumni Association

Retrieved on: 
Wednesday, March 31, 2021
Lobe

Vancouver, British Columbia--(Newsfile Corp. - March 31, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce it has become an official Enterprise Member of the NFL Alumni Association.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - March 31, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce it has become an official Enterprise Member of the NFL Alumni Association.
  • As an Enterprise Member of The NFL Alumni Association (the "NFLAA"), Lobe is able to engage with those who built the NFLAA brand, and who's clients and customers readily recognize their charitable work.
  • Philip Young, CEO and Director of Lobe stated, "As an Enterprise Member of the NFL Alumni Association, we look forward to supporting their organization and working with the team and their advisors helping to identify more efficient ways of identifying players at risk of or battling various mental health challenges, traumatic brain injuries, and PTSD."
  • "We are privileged to have Lobe join our enterprise program to help us "Care For Our Own".

SmallCapsDaily: Lobe Sciences is a Major Opportunity In the Psychedelics Medicine Industry

Retrieved on: 
Friday, February 12, 2021
Pharmaceutical industry, Lobe, Drug delivery, Drug, Medication, Natural sciences

Highlighted in the SmallCapsDaily reporting, is the unique company overview and the core offerings of Lobe Sciences.

Key Points: 
  • Highlighted in the SmallCapsDaily reporting, is the unique company overview and the core offerings of Lobe Sciences.
  • Additionally, Lobe is working towards creating devices and improved delivery mechanisms for the efficient application of medications.
  • Lobe has intellectual property and has strategically acquired brands related to the psychedelic drug therapy industry, which can lead to lucrative licensing and partnerships.
  • The SmallCapsDaily coverage of Lobe Sciences proves to be a comprehensive exploration of the company's unique IP assets, its positioning within the industry and the opportunity Lobe represents to stakeholders monitoring changes within the psychedelic medicine, drug therapy and drug delivery industries.

Lobe Sciences Announces Management Changes and New Director

Retrieved on: 
Monday, January 18, 2021
Lobe, FL

Appointment of Philip Young as CEO and director adds a seasoned executive with a track record of new device and therapeutics development, FDA/regulatory approvals, capital markets, M&A and operational success

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - January 18, 2021) - Lobe Sciences Ltd (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce the appointment of Mr. Philip J.
  • Prior to Exactus, Mr. Young was the president, CEO, and Director of AmpliPhi Biosciences Corp. (now Armata Pharmaceuticals Inc.), a global biopharmaceutical company.
  • Jonathan Gilbert, Executive Chairman of Lobe, states, "We are very pleased to have Philip join our Lobe executive team.
  • Lobe is a growth-oriented research, technology & services company that provides financial, management, IP and branding support to businesses.